Anti-TNF Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease
2019
ABSTRACTBackground:Vedolizumab (VDZ) is effective for treating both adult and pediatric onset IBD. Clinical outcomes, however, have been reported to be superior in patients naive to anti-TNF. With the growing interest in endoscopic endpoints, we aimed to describe rates of mucosal healing in pediatri
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
8
Citations
NaN
KQI